| Other Abstract | Objective: To explore the influential factors of disease-free interval(DFI) in ovarian cancer after primary treatment , the correlation of disease-free interval and overall survival (OS) and the prognosis of the different treatment in patients with recurrent ovarian cancer. To provide information and evidence for understanding the laws of ovarian cancer recurrence, prolonging the disease-free interval and overall survival , electing treatment programs after relapse.
Methods: Clinical information of 56 patients with recurrent ovarian cancer in the First Hospital of Lanzhou University between January 2009 and December 2014 were reviewed retrospectively. Analysis of six factors on the influential of disease-free interval: pathological pattern, age, histological grade, clinical stage, the chemotherapy courses after initial cytoreductive surgery, the size of the residual tumor after initial cytoreductive surgery.56 patients were divided into two groups, 22 patients were treated with secondary cytoreductive surgery （SCS）combined with chemotherapy (Surgery group), 34 patients were treated with Salvage chemotherapy (chemotherapy group) depend on different treatment method. Analysis of two groups of patients prognosis.
Results: (1) Pathological pattern, histological grade, clinical stage, the chemotherapy courses after initial cytoreductive surgery, the size of the residual tumor after initial cytoreductive surgery are associated with DFI(P<0.05)with single fact analysis.Age is not related to DFI (P=0.633). Histological grade lower,Clinical stage earlier, regular and full courses of chemotherapy, the residual tumor after initial cytoreductive surgery smaller, the DFI will be longer.Clinical stage and the size of the residual tumor after initial cytoreductive surgery are associated with DFI with multiple fact analysis(P<0.05) ， they are the independent influential factors of DFI. (2) DFI and OS are positive correlation（r=0.929，P<0.01）,Longer the DFI,Longer the OS.(3)The median overall survival of 56 patients is 38 month, median survival time after relapse is 20.5 month.The one-year,two-year, three-year,four-year five year survival rate of 56 patients are 93%,75%,59%,44% ,29% respectively.The median survival time after relapse of Surgery group is 30 months, which is significantly longer than patients in chemotherapy group (16 month, 2=10.849, P<0.05). The one-year,two-year, three-year,four-year survival rate of chemotherapy group are 65%,32%,8%,0... |
